IS20I, a specific αvβ3 integrin inhibitor, reduces glioma growth in vivo

Neurosurgery

Volumn 52, Issue 1, 2003, Pages 177-186

  Bello, Lorenzo ^a   Lucini, Valeria ^a   Giussani, Carlo ^a   Carrabba, Giorgio ^a   Pluderi, Mauro ^a   Scaglione, Francesco ^a   Tomei, Giustino ^a   Villani, Roberto ^a   Black, Peter Mc L ^c   Bikfalvi, Andreas ^b   Carroll, Rona S ^c   Zlokovic, Berislav ^c   Piepmeier, Joseph M ^c   Glick, Roberta ^c   Lichtor, Terry ^c  

^a UNIVERSITY OF MILAN   (Italy)

^b UNIVERSITÉ DE BORDEAUX   (France)

^c University of Bordeaux I ^*

Author keywords

Angiogenesis; Glioma; IS20I; Migration; Proliferation

Indexed keywords

ALPHA V BETA3 INTEGRIN INHIBITOR; ANTIBODY; ANTINEOPLASTIC AGENT; FIBROBLAST GROWTH FACTOR NEUTRALIZING ANTIBODY; IS 201; MONOCLONAL ANTIBODY LM 609; NEUTRALIZING ANTIBODY; UNCLASSIFIED DRUG; VITRONECTIN ANTIBODY; CYCLOPEPTIDE; IS20I; OLIGOPEPTIDE; VITRONECTIN RECEPTOR;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CANCER GROWTH; CELL ADHESION; CELL MIGRATION; CELL PROLIFERATION; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; DRUG MECHANISM; DRUG POTENCY; DRUG SELECTIVITY; ENDOTHELIUM CELL; GLIOBLASTOMA; GROWTH INHIBITION; HUMAN; HUMAN CELL; IN VIVO STUDY; MOUSE; NONHUMAN; NUDE MOUSE; PRIORITY JOURNAL; TUMOR CELL; TUMOR VASCULARIZATION; ANIMAL; BRAIN TUMOR; CANCER INVASION; CANCER TRANSPLANTATION; CELL CULTURE; CELL DIVISION; CELL MOTION; CELL SURVIVAL; CHEMISTRY; DRUG ANTAGONISM; GLIOMA; NEOVASCULARIZATION (PATHOLOGY); PATHOLOGY; VASCULAR ENDOTHELIUM;

ANIMALS; ANTINEOPLASTIC AGENTS; BRAIN NEOPLASMS; CELL ADHESION; CELL DIVISION; CELL MOVEMENT; CELL SURVIVAL; ENDOTHELIUM, VASCULAR; GLIOMA; HUMANS; INTEGRIN ALPHAVBETA3; MICE; MICE, NUDE; NEOPLASM INVASIVENESS; NEOPLASM TRANSPLANTATION; NEOVASCULARIZATION, PATHOLOGIC; OLIGOPEPTIDES; PEPTIDES, CYCLIC; TUMOR CELLS, CULTURED;

EID: 0037209122     PISSN: 0148396X     EISSN: None     Source Type: Journal    
DOI: 10.1097/00006123-200301000-00023     Document Type: Article

References (31)

1. Bello L, Francolini M, Marthyn P, Zhang J, Carroll RS, Nikas DC, Strasser JF, Villani R, Cheresh DA, Black PMcL: αvβ3 and αvβ5 integrin expression in glioma periphery. Neurosurgery 49:380-390, 2001.
2. Brooks PC: Role of integrins in angiogenesis. Eur J Cancer 32A:2423-2429, 1996.
3. Brooks PC, Clark RA, Cheresh DA: Requirement of vascular integrin αvβ3 for angiogenesis. Science 264:569-571, 1994.
4. Brooks PC, Montgomery AM, Rosenfeld M, Reisfeld RA, Hu T, Klier G, Cheresh DA: Integrin αvβ3 antagonists promote tumor regression by inducing apoptosis of angiogenic blood vessels. Cell 79:1157-1164, 1994.
5. Brooks PC, Stromblad S, Klemke R, Visscher D, Sarkar FH, Cheresh DA: Antiintegrin αvβ3 blocks human breast cancer growth and angiogenesis in human skin. J Clin Invest 96:1815-1822, 1995.
6. Brooks PC, Stromblad S, Sanders LC, von Schalscha TL, Aimes RT, Stetler-Stevenson WG, Quigley JP, Cheresh DA: Localization of matrix metalloproteinase MMP-2 to the surface of invasive cells by interaction with integrin αvβ3. Cell 85:683-693, 1996.
7. Chatterjee S, Matsumura A, Schradermeier J, Gillespie GY: Human malignant glioma therapy using anti-αvβ3 integrin agents. J Neurooncol 46:135-144, 2000.
8. Cheresh DA: Structure, function and biological properties of integrin αvβ3 on human melanoma cells. Cancer Metastasis Rev 10:3-10, 1991.
9. Cheresh DA, Spiro RC: Biosynthetic and functional properties of an Arg-Gly-Asp-directed receptor involved in human melanoma cell attachment to vitronectin, fibrinogen, and von Willebrand factor. J Biol Chem 262:17703-17711, 1987.
10. Deroanne CF, Hajitou A, Calberg-Bacq CM, Nusgens BV, Lapiere CM: Angiogenesis by fibroblast growth factor 4 is mediated through an autocrine up-regulation of vascular endothelial growth factor expression. Cancer Res 57:5590-5597, 1997.
11. Deryugina EI, Bourdon MA, Luo GX, Reisfeld RA, Strongin A: Matrix metalloproteinase-2 activation modulates glioma cell migration. J Cell Sci 110:2473-2482, 1997.
12. Friedlander M, Brooks PC, Shaffer RW, Kincaid CM, Varner JA, Cheresh DA: Definition of two angiogenic pathways by distinct av integrins. Science 270:1500-1502, 1995.
13. Friedlander DR, Zagzag D, Shiff B, Cohen H, Allen JC, Kelly PJ, Grumet M: Migration of brain tumor cells on extracellular matrix proteins in vitro correlates with tumor type and grade and involves αv and β1 integrins. Cancer Res 56:1939-1947, 1996.
14. Gladson CL, Wilcox JN, Sanders L, Gillespie GY, Cheresh DA: Cerebral microenvironment influences expression of the vitronectin gene in astrocytic tumors. J Cell Sci 108:947-956, 1995.
15. Hanahan D, Folkman J: Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 86:353-364, 1996.
16. Joki T, Heese O, Nikas DC, Bello L, Zhang J, Kraeft SK, Seyfried NT, Abe T, Chen LB, Carroll RS, Black PMcL: Expression of cyclooxygenase 2 (COX-2) in human glioma and in vitro inhibition by a specific COX-2 inhibitor, NS-398. Cancer Res 60:4926-4931, 2000.
17. Kumar CC, Malkowski M, Yin Z, Tanghetti E, Yaremko B, Nechuta T, Varner J, Liu M, Smith EM, Neustadt B, Presta M, Armstrong L: Inhibition of angiogenesis and tumor growth by SCH221153, a dual αvβ3 and αvβ5 integrin receptor antagonist. Cancer Res 61:2232-2238, 2001.
18. Leon SP, Folkerth RD, Black PMcL: Microvessel density is a prognostic indicator for patients with astroglial brain tumors. Cancer 77:362-372, 1996.
19. MacDonald TJ, Taga T, Shimada H, Tabrizi P, Zlokovic BV, Cheresh DA, Laug WE: Preferential susceptibility of brain tumors to the antiangiogenic effects of an αv integrin antagonist. Neurosurgery 48:151-157, 2001.
20. Miller WH, Alberts DP, Bhatnagar PK, Bondinell WE, Callahan JF, Calvo RR, Cousins RD, Erhard KF, Heerding DA, Keenan RM, Kwon C, Manley PJ, Newlander KA, Ross ST, Samanen JM, Uzinskas IN, Venslavsky JW, Yuan CCK, Haltiwanger RC, Gowen M, Hwang SM, James IE, Lark MW, Rieman DJ, Stroup GB, Azzarano LM, Salyers KL, Smith BR, Ward KW, Johanson KO, Huffman WF: Discovery of orally active nonpeptide vitronectin receptor antagonists based on a 2-benzazepine Gly-Asp mimetic. J Med Chem 43:22-26, 2000.
21. Miller WH, Bondinell WE, Cousins RD, Erhard KF, Jakas DR, Keenan RM, Ku TW, Newlander KA, Ross ST, Haltiwanger RC, Bradbeer J, Drake FH, Gowen M, Hoffman SJ, Hwang SM, James IE, Lark MW, Lechowska B, Rieman DJ, Stroup GB, Vasko-Moser JA, Zembryki DL, Azzarano LM, Adams PC, Salyers KL, Smith BR, Ward KW, Johanson KO, Huffman WF: Orally bioavailable nonpeptide vitronectin receptor antagonists with efficacy in an osteoporosis model. Bioorg Med Chem Lett 9:1807-1812, 1999.
22. Mitjans F, Meyer T, Fittschen C, Goodman S, Jonczyk A, Marshall JF, Reyes G, Piulats J: In vivo therapy of malignant melanoma by means of antagonists of αv integrins. Int J Cancer 87:716-723, 2000.
23. Miyamoto S, Teramoto H, Gutkind JS, Yamada KM: Integrins can collaborate with growth factors for phosphorylation of receptor tyrosine kinases and MAP kinase activation: Roles of integrin aggregation and occupancy of receptors. J Cell Biol 135:1633-1642, 1996.
24. Nicholas MK, Prados MD, Larson DA: Malignant astrocytomas, in Black PMcL, Loeffler JS (eds); Cancer of the Nervous System. Cambridge, Blackwell Science, 1997, pp 464-491.
25. Rusnati M, Tanghetti E, Dell'Era P, Gualandris A, Presta M: αvβ3 integrin mediates the cell-adhesive capacity and biological activity of basic fibroblast growth factor (FGF-2) in cultured endothelial cells. Mol Biol Cell 8:2449-2461, 1997.
26. Schneller M, Vuori K, Ruoslahti E: αvβ3 integrin associates with activated insulin and PDGFβ receptors and potentiates the biological activity of PDGF. EMBO J 16:5600-5607, 1997.
27. Senger DR, Ledbetter SR, Claffey KP, Papadopoulos-Sergiou A, Peruzzi CA, Detmar M: Stimulation of endothelial cell migration by vascular permeability factor/vascular endothelial growth factor through cooperative mechanisms involving the αvβ3 integrin, osteopontin, and thrombin. Am J Pathol 149:293-305, 1996.
28. Tonn JC, Wunderlich S, Kerkau S, Klein CE, Roosen K: Invasive behaviour of human gliomas is mediated by interindividually different integrin patterns. Anticancer Res 18:2599-2605, 1998.
29. Waltenberger J, Claesson-Welsh L, Siegbahn A, Shibuya M, Heldin CH: Different signal transduction properties of KDR and Flt1, two receptors for vascular endothelial growth factor. J Biol Chem 269:26988-26995, 1994.
30. Walton HL, Corjay MH, Mohamed SN, Mousa SA, Santomenna LD, Reilly TM: Hypoxia induces differential expression of the integrin receptors αvβ3 and αvβ5 in cultured human endothelial cells. J Cell Biochem 78:674-680, 2000.
31. Weidner N, Semple JP, Welch WR, Folkman J: Tumor angiogenesis and metastasis: Correlation in invasive breast carcinoma. N Engl J Med 324:1-8, 1991.